Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Nick who wrote (2312)	5/28/1998 11:17:00 AM
From: invest04	Respond to of 5736

Nick...the nice thing about CCSI is that there are relatively few shares outstanding, and of those outstanding, a very high percentage are held by a relatively few number of institutions and individuals. I think I've got a pretty good handle on who is holding what, and I figure that the real hard float is somewhere between 2 1/4 to 2 1/2 million shares. So yes, the short interest does exceed the real hard float on CCSI. Those relatively few institutions and individuals holding the vast majority of shares are not your mom and pop investors or traders. They aren't "scared off" by the size of the short interest, cause they know what they know about CCSI, and the implication that shorts know something else is totally bogus. Similarly, being sophisticated investors and traders, they have managed their accounts so a margin call is not a factor, nor are the bs comments posted here and elsewhere.

To: Nick who wrote (2312)	5/28/1998 11:47:00 AM
From: Gurupup	Respond to of 5736

I never assume that short sellers are stupid. I hopefully assume they have not done all of the required due diligence required, although in this case, I am surprised they keep pressing their bets, when neither side has any further information. IMO, the short case is the following. 1. Darby is not a good manager, and is a woman. The facts in both cases speak for themselves. She has brought the company to this stage on her determination and belief in her product, and her strong feelings for shareholder values. I daresay few other CEO's could or would have accomplished what she has done with her work ethic, and her very competent staff. 2. SPRX is competition. BS> They are a non-event in the medical arena, according to the medical community. 3. We do not have a partner. I believe this point will be addressed in the near future, with a deal that will outline what the worldwide potential for Tlc.bili will be. 4. Pediatricians do not want the product. I personally as well as my associates have over a hundred examples that prove that to be very incorrect. 5. Push is coming to shove, and shortly the burden of proof is going to be on the shorts shoulders, and we are going to have a one way street for awhile as they scramble for their next method of attack. They will not go away, but they will be severely hurt, and will have to regroup with a new method of attack. Their initial reasons for shorting, as well as Avalon's garbage will be history. 6. I only have one suggestion left. Try and do some due diligence on other medical device companies, or bio-tech deals in the past. In a while let's compare notes on how those deals were done, and the structure of those deals. Perhaps that will give us all an indication of how good our deal might be when it is completed.